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Abstract
It has been long established that post-mastectomy radiotherapy reduces the risk of locoregional
failure. A survival advantage, however, has only recently been demonstrated. We here provide a
review of the literature as regards to the current indications for post-mastectomy radiotherapy.
Current indications for post-mastectomy 
radiation
Primary breast carcinoma may be managed surgically with
either mastectomy or breast conserving surgery. Although
radiotherapy following breast conserving surgery is widely
accepted, the role of post-mastectomy radiotherapy
(PMRT) has been a subject for debate for many years.
PMRT has been known since the 1970's to substantially
reduce the risk of locoregional failure (LRF), however, a
disease specific survival and overall survival advantage has
only more recently been demonstrated [1-5]. The systemic
therapy of breast cancer has also evolved since many of
the studies were conducted, raising the issue of how best
to incorporate PMRT into current clinical practice.
Randomized control studies of PMRT have consistently
reported improved rates of locoregional control by two-
thirds regardless of patient characteristics such as age,
treatment era or disease characteristics [5-7]. Only in the
late 1990's was it noted that PMRT conveyed a survival
advantage in high risk patients treated with adjuvant
chemotherapy or hormonal therapy [1-5]. The Danish
82b study of PMRT in premenopausal women receiving
adjuvant CMF chemotherapy reported a reduction in LRF
(9% v. 32%, p < 0.001) and improved 10 year overall sur-
vival (54% v. 45%, p < 0.001) in patients receiving PMRT
[2] with similar results reported in the British Columbia
study [1]. The Danish 82c study assessing PMRT in post-
menopausal women receiving one year adjuvant
tamoxifen also revealed similar reductions in LRF (8% v.
35%, p < 0.001) and improved 10 year overall survival
(45% v. 36%, p = 0.03) [3].
There are a number of reasons why a survival advantage
may not have initially been apparent. Original studies
were conducted in the era prior to adjuvant systemic ther-
apy. The resulting reduction of distant failure with sys-
temic therapy may allow the survival effect of PMRT to be
more evident. Analysis of cause-specific mortality in the
older PMRT studies revealed that the reduction in breast
cancer deaths was cancelled out by an increase in late car-
diac mortality secondary to radiotherapy [6,7]. With mod-
ern radiotherapy techniques delivery of dose to the chest
wall is more uniform and cardiac dose minimized. Older
studies were also not stratified according to risk and being
of small sample size not powered sufficiently to detect a
small survival advantage.
The absolute benefit gained from PMRT is believed great-
est for those at high risk of LRF. There is consensus that
PMRT should be considered when risk of LRF is greater
than 20%, such as for patients with four or more positive
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T4 disease and positive/very close margin [8-11]. PMRT is
not indicated in patients with tumours less than 5 cm in
size and negative axillary nodes as there is only small ben-
efit in terms of locoregional control, and insignificant
absolute survival advantage. Several studies have sug-
gested other factors that may contribute to risk of LRF par-
ticularly when present in combination [8-11]. These
include age less than 40 years, histological grade 3
tumours, presence of lymphovascular invasion, less than
6 nodes removed at axillary dissection and significant
nodal extracapsular spread (> 2 mm). The merit of PMRT,
however, in this group of patients is not known.
It remains unclear whether patients with one to three axil-
lary nodes positive benefit significantly from PMRT. A
number of collaborative groups (including the Eastern
Cooperative Oncology Group, the International Breast
Cancer Study Group and the National Surgical Adjuvant
Breast and Bowel Project) have reported patterns of LRF
following mastectomy in a number of their trials and have
reported that this group of patients experience a LRF rate
of 13–19% compared with 30–33% as reported in the key
randomised trials [8-11]. This discrepancy may be
explained by limited axillary dissection underestimating
the true extent of axillary nodal involvement as only a
median of 7 axillary nodes were removed in the Danish
study and 11 nodes in the British Columbia study com-
pared with 15–17 nodes in these other studies (which
were not directly investigating the value of PMRT). A sub-
set analysis of the Danish 82 b and c studies has been per-
formed including only those with 8 or more axillary
nodes removed reporting continued significant and equal
reductions in LRF and overall survival at 15 years with
PMRT in both the one to three and greater than four
involved node groups[4]. LRF, however, remained high in
the subgroup analysed and the caveat remains that the
extent of adjuvant systemic therapy received in the Danish
studies was less than current clinical practice which may
affect the perceived benefit of PMRT in this group. To
resolve whether patients with one to three positive axillary
nodes should undergo PMRT a phase III randomised con-
trol trial – the Selective Use of Post-operative Radiother-
apy after Mastectomy (SUPREMO) trial – is currently
being conducted in Europe randomising patients with
tumours less than 5 cm in size and 0–3 positive axillary
nodes.
The commonest site of LRF following mastectomy and
axillary nodal dissection is the chest wall (50–75%) fol-
lowed by the supraclavicular fossa and infraclavicular
region (20–40%) [8,9]. The rate of axillary recurrence fol-
lowing a level I/II axillary dissection is < 5% at 10 years
[12,13] and as such the axilla is not routinely irradiated as
part of PMRT. Furthermore, irradiating the entire axilla
following axillary dissection would significantly increase
the rate of chronic arm morbidity and lymphoedema
[14,15].
Irradiation of the internal mammary nodal region
remains controversial. Clinical evidence of recurrence at
this site appears uncommon [8-11] despite older surgical
reports suggesting high rates of involvement [16,17]. The
Danish and British Columbia studies incorporated inter-
nal mammary nodal irradiation [1-3] but its contribution
to survival is unclear. There remains a particular concern
regarding radiation dose to the heart from treatment of
the internal mammary chain and thereby increased risk of
late cardiac toxicity. Results from the European Organisa-
tion for Research and Treatment of Cancer (EORTC)
22922 and the National Cancer Institute of Canada Clin-
ical Trials Group (NCIC CTG) MA20 randomised trials
may provide further clarification.
Systemic therapy of early breast cancer has evolved con-
siderably since many of the PMRT studies were conducted.
Women are more likely to receive more cardiotoxic adju-
vant systemic therapy. There is a significant survival
advantage to anthracyline based regimens compared to
CMF [18], and as a result anthracyclines are now routinely
incorporated into most adjuvant chemotherapy sched-
ules. High risk patients may also receive taxanes following
evidence of a further survival advantage when added to
anthracyclines [19,20]. Furthermore, recent studies have
demonstrated a survival benefit from the addition of tras-
tuzumab in patients with HER2-positive tumours [21,22].
The potential cardiotoxicity of trastuzumab is now well-
established. Whether PMRT offers a further advantage in
patients receiving optimal systemic adjuvant therapy is
unclear. However, the MD Anderson Cancer Center and
the NSABP series assessing locoregional recurrence in
patients receiving anthracycline based chemotherapy sug-
gest that locoregional failure remains an important con-
cern [9,11]. The current recommended duration of
adjuvant hormonal therapy is 5 years, compared to one as
in the Danish 82c study, which may also have an impact
on LRF. Furthermore, in postmenopausal women, the
aromatase inhibitors (AIs) are increasingly being used
instead of tamoxifen. AIs have been shown to reduce both
local and distal relapse compared to tamoxifen [23-26].
Conclusion
PMRT reduces the risk of LRF and increases overall sur-
vival in high risk patients. Current indications for PMRT
include axillary nodal involvement of 4 or more nodes,
disease 5 cm or more in size, T4 disease and positive sur-
gical margins. The potential benefits of PMRT in patients
with < 4 positive axillary nodes remain controversial and
recruitment to ongoing clinical trials should be encour-
aged.Page 2 of 4
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